Annexon (ANNX) Profit After Tax (2019 - 2026)
Annexon (ANNX) posted quarterly Profit After Tax of -$44.1 million for Q1 2026, up 18.94% year-over-year from -$37.1 million in Q1 2025, and up 8.44% quarter-over-quarter from -$48.2 million in Q4 2025.
Annexon (ANNX) Profit After Tax (2019 - 2026) Analysis & Trends
Annexon's Profit After Tax history runs 8 years deep, the most recent figure standing at -$44.1 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 18.94% year-over-year to -$44.1 million; the TTM figure through Mar 2026 stood at -$196.4 million (down 17.28% YoY), while the FY2025 annual figure was -$206.7 million, down 49.59% from the prior year.
- Profit After Tax for Q1 2026 stood at -$44.1 million, up from -$48.2 million in the prior quarter.
- The five-year high for Profit After Tax was -$25.2 million in Q1 2024, with the low at -$54.9 million in Q3 2025.
- The 5-year median for Profit After Tax is -$35.4 million (2022), against an average of -$39.1 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 34.91% in 2024, then sank 116.31% in 2025.
- Annexon's Profit After Tax stood at -$34.2 million in 2022, then climbed by 18.34% to -$27.9 million in 2023, then sank by 74.21% to -$48.6 million in 2024, then grew by 0.78% to -$48.2 million in 2025, then climbed by 8.44% to -$44.1 million in 2026.
- Business Quant data shows ANNX's Profit After Tax at -$44.1 million in Q1 2026, -$48.2 million in Q4 2025, and -$54.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | -55.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.35 Mn |
| Mar 31, 2026 | -44.14 Mn |
| Dec 31, 2025 | -48.21 Mn |
| Sep 30, 2025 | -54.92 Mn |
| Jun 30, 2025 | -49.16 Mn |
| Mar 31, 2025 | -54.46 Mn |
| Dec 31, 2024 | -48.59 Mn |
| Sep 30, 2024 | -34.82 Mn |
| Jun 30, 2024 | -29.61 Mn |
| Mar 31, 2024 | -25.18 Mn |
| Dec 31, 2023 | -27.89 Mn |
| Sep 30, 2023 | -32.48 Mn |
| Jun 30, 2023 | -35.19 Mn |
| Mar 31, 2023 | -38.68 Mn |
| Dec 31, 2022 | -34.16 Mn |
| Sep 30, 2022 | -35.05 Mn |
| Jun 30, 2022 | -37.14 Mn |
| Mar 31, 2022 | -35.37 Mn |
| Dec 31, 2021 | -37.47 Mn |
| Sep 30, 2021 | -35.61 Mn |